Blinatumomab

From WikiMD.org
Jump to navigation Jump to search

Blinatumomab (pronounced as blih-NOO-toh-MOH-bab) is a type of biopharmaceutical used in the treatment of certain types of cancer, specifically acute lymphoblastic leukemia (ALL).

Etymology

The name "Blinatumomab" is derived from its nature as a bispecific T-cell engager (BiTE), with "blin" referring to "bispecific lymphocyte engager" and "mab" standing for "monoclonal antibody".

Usage

Blinatumomab is used to treat B-cell precursor ALL, a type of blood and bone marrow cancer. It is used when the cancer has come back or has not gone away after treatment (refractory). It is a type of monoclonal antibody and a type of bispecific T cell engager.

Mechanism of Action

Blinatumomab works by linking B cells and T cells together, which allows the T cells to attack and kill the cancerous B cells. This is achieved through the dual affinity of the drug, which binds to both CD19 on the B cells and CD3 on the T cells.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski